沙利度胺联合英夫利西治疗克罗恩病患者的临床效果

Clinical effect of thalidomide combined with infliximab in the treatment of patients with Crohn’s disease

目的研究沙利度胺联合英夫利西治疗克罗恩病患者的临床效果。方法选择2017年9月至2018年9月我院收治的106例克罗恩病患者为研究对象,采用随机数字法将其分为英夫利西组(53例,英夫利西)和沙利度胺+英夫利西组(53例,沙利度胺联合英夫利西)。比较两组的临床疗效。结果治疗2个月后,沙利度胺+英夫利西组的IFN-γ、TNF-ɑ、IL-8、CRP、VEGF水平、CDAI评分、ESR、CD4^+、CD3^+及不良反应总发生率明显低于英夫利西组,CD8^+和临床治疗总有效率明显高于英夫利西组(P<0.05)。结论克罗恩病患者应用沙利度胺联合英夫利西治疗的效果显著,可推广应用。

Objective To study the clinical effect of thalidomide combined with infliximab in the treatment of patients with Crohn’s disease. Methods A total of 106 cases of Crohn’s disease patients admitted in our hospital from September 2017 to September 2018 were selected as the research objects and divided into infliximab group(53 cases, infliximab) and thalidomide+infliximab group(53 cases, thalidomide combined with infliximab) by the random number method. The clinical curative effects were compared between the two groups. Results After 2 months treatment, IFN-γ, TNF-ɑ, IL-8, CRP,VEGF levels, CDAI score, ESR, CD4^+, CD3^+and total incidence of adverse reaction in the thalidomide+infliximab group were significantly lower than those in the infliximab group;CD8^+and the total effective rate of clinical treatment were significantly higher than those in the infliximab group(P<0.05). Conclusion Thalidomide combined with infliximab in the treatment of Crohn’s disease patients has a remarkable effect, which can be promotion and application.